A series of 9,1 1-cyclic acetal derivatives of (9<S)-9-dihydroerythromycin A (4) have been prepared and their antibacterial activities compared to those of erythromycin A and 9-dihydroerythromycin A. Manyof the cyclic acetal derivatives showedbetter antibacterial activity than their parent 4. In particular, the acetaldehyde acetal (9-0,1 l-O-ethylidene-9-dihydroerythromycin A) (8b) showed good antibacterial activity in comparison with erythromycin A but was not sufficiently improved in vivo to warrant progression.
A series of 9,1 1-cyclic acetal derivatives of (9<S)-9-dihydroerythromycin A (4) have been prepared and their antibacterial activities compared to those of erythromycin A and 9-dihydroerythromycin A. Manyof the cyclic acetal derivatives showedbetter antibacterial activity than their parent 4. In particular, the acetaldehyde acetal (9-0,1 l-O-ethylidene-9-dihydroerythromycin A) (8b) showed good antibacterial activity in comparison with erythromycin A but was not sufficiently improved in vivo to warrant progression.
The nature of the substituent at position 9 in derivatives of erythromycin A (1) can have a marked effect on antibacterial activity. Thus erythromycin (1) and its 9-carbonyl condensation products, such as the 9-oxime 21} and 9-hydrazone 32), are all highly active against Gram-positive bacteria, whereas the reduced product, (96')-9-dihydroerythromycin A (4)3), has much weaker activity. In contrast to the alcohol 4, the corresponding 9-amine, (9S)-erythromycylamine A (5)4), is quite active. Also, those derivatives of 5 which retain a basic nitrogen at C-9 have good activity, whereas the 9-epimer of 5 and those derivatives of 5 which contain a non-basic nitrogen at C-9 have poor activity4*5). Wenowdescribe a series of 9,ll-cyclic acetal derivatives of (95)-9-dihydroerythromycin (4), some of which, in contrast to 4 itself, have quite good antibacterial activity.
The simplest representative of this type of acetal, the methylene acetal 8a, was prepared by way of reaction of the bis-protected des-A^methyl-9-dihydroerythromycin 6 with chloroiodomethane and sodium hydride to give the methylene acetal 7, followed by deprotection and reductive JV-methylation6) to give 8a. Other acetals, as detailed in Table 1 , were prepared by acid-catalysed acetalisation of either 9-dihydroerythromycin (4) or the TV-protected form 6 with the appropriate aldehyde, or by an acid-catalysed transacetalisation using 9-dihydroerythromycin (4) and the dimethyl acetal of the aldehyde. All of the acetals in Table 1 were obtained as single diastereoisomers. Although the stereochemistry at the acetal carbon in these compoundsis unknown, the correspondence of 13C chemical shifts would imply that they all have the same stereochemistry at this centre. Fromthermodynamic considerations, the R configuration would be suggested (i.e. an equatorial configuration for the substituent on the methylenedioxy carbon of a chair-shaped 1,3-dioxane ring). The acetonide 9 was prepared by reaction of 9-dihydroerythromycin (4) and methyl isopropenyl ether in the presence of acid.
For comparison with the above acetals, three other compoundswere prepared. The 9,ll-cyclic carbonate 10 was obtained by reaction of 9-dihydroerythromycin (4) with carbonyl diimidazole. The cyclic ortho ester 8m was prepared by treating 4 with trimethyl orthoformate in the presence of acid; in contrast to the acetals 8b~81, the orthoformate 8mwas obtained as an inseparable mixture of two diastereoisomers. The 9-ether ll was prepared from the iV-protected 9-dihydroerythromycin 6 by reaction with sodium hydride and 2-methoxyethoxymethyl chloride, followed by the usual deprotection ). c Satisfactory microanalytical data were determined (except for 8d and 8e, which were gums).
-: Not measured. Organisms: S.a., Staphylococcus aureus Oxford; S.p., Streptococcus pneumoniae 1761 ; S.f., Streptococcusfaecalis I ; HA., Haemophilus influenzae Wy21 ; B.C., Branhamella catarrhalis 1 502. and reductive JV-methylation.
The antibacterial activities of the new derivatives are shown in Table 2 . The best of the 9,llcyclic acetals was the ethylidene derivative 8b, which had good activity when compared with erythromycin (1) and was significantly more active than the parent 9-dihydroerythromycin (4). The other 9,1 1-cyclic derivatives in Table 2 were generally less active than the ethylidene derivative 8b, although manyof them were more active than 9-dihydroerythromycin (4), especially against Staphylococcus aureus and Streptococcus pneumoniae.In contrast to the cyclic compounds,the non-cyclic 9-ether ll had very poor activity, being even less active than the parent 9-alcohol 4.
The ethylidene derivative 8b was also tested against experimental infections (S. aureus and S. pneumoniae) in mice, where it proved to be marginally more active than erythromycin. This improvement over erythromycin was insufficient for the compound to be progressed further.
Exp eriment al MP's were determined using a Kofler hot-stage apparatus. Specific rotations were measured for solutions in CHC13. Electron impact mass spectra (EI-MS) were obtained on a VGZABIF mass spectrometer operated at 8 kV using 70 eV electrons and a source temperature of 200°C. The structures of all compounds were confirmed by XHand 13C NMRspectra for solutions in CDC13.
Solutions were dried with anhydrous sodium sulfate and solvents were evaporated using a rotary evaporator with bath temperature below 30°C. Except where stated otherwise, Merck Silica gel 60 was used for column chromatography. For chromatography on silanised silica gel, Merck Silica gel 60H silanised was used.
( FEB. 1989 (30 ml) was stirred at -15°C while sodium borohydride (150 mg) was added in small portions during 1 hour. The mixture was stirred for a further 1.5 hours during which the temperature was allowed to rise to 0°C. Acetic acid (2 ml) was added and the mixture was stirred for 5 minutes. The mixture was diluted with ethyl acetate (150 ml) and was washed with water, satd NaHCO3, and water. The solution was dried, the solvent was removed, and the residue was crystallised from Et2O -hexane to give the title compound as colourless crystals ( 
A (6) (800 mg) in dry DMF(10 ml) was treated with K2CO3 powder (500 mg), 15-crown-5-ether (1,4,7,10,13-pentaoxacyclopentadecane) (2 drops), and chloroiodomethane (1 ml). The mixture was stirred at 0°C while sodium hydride (50% dispersion in oil; 100 mg) was added in one portion. The mixture was stirred at 0°C for 30 minutes and was then allowed to warm to room temperature during 10 minutes. The mixture was diluted with ethyl acetate (100 ml) and was washed with Na2SO3 soln (30 ml) and water (3 x40 ml).
The solution was dried, the solvent was removed, and the residue was chromatographed using EtOAchexane to give the title compound as a white solid. Crystallisation from Et2O -hexane gave 7 as colourless crystals (520 mg (
95)-9-O, l l -O-Methylene-9-dihydroerythromycin A (8a) (95)-2/-O, 3 /-A^-Bis(benzyloxycarbonyl)-A^-demethyl-9-
O , l l -O-methylene-9-dihydroerythromycin A (7) (500 mg) in EtOH (20 ml) and acetate buffer (pH 4.8, 0.73 m, 2 ml) was shaken with 10% palladiumcarbon (150mg) under hydrogen (1 atmosphere) for 30 minutes. 37% formaldehyde (2 ml) was added and hydrogenation was continued for 1.5 hours. The catalyst was removed by filtration and was washed with EtOH and water. The EtOH was removed from the filtrate under reduced pressure, and the aqueous solution was diluted with water, basified (pH 12) using K2CO3, and extracted with ethyl acetate (3 x40 ml). The combined extracts were washed with water and dried. The solvent was removed to yield a white foam (380 mg). Crystallisation from CH2C12-hexane gave the title compound as colourless crystals (340 mg ) and pyridinium /?-toluenesulfonate (360 mg) in acetaldehyde (5 ml) were treated with anhydrous copper (II) sulfate (1.0 g) and the mixture was stirred for 10 days. The mixture was diluted with ethyl acetate (50 ml) and washed with 10% K2CO3 soln (30 ml) and water (3 x30 ml). The solution was dried, the solvent was removed, and the residue was chromatographed on silanised silica gel using MeOH-phosphate buffer (0.067 m, pH 7.0) (3 : 2) to give the title compound as colourless crystals (500 mg A (6) (500 mg) and pyridinium^-toluenesulfonate (70 mg) were dissolved in a mixture of 1,2-dimethoxyethane (5 ml) and propionaldehyde (5 ml). Anhydrous calcium sulfate (l.O g) was added and the mixture was stirred for 10 days. The mixture was diluted with ethyl acetate (50 ml) and filtered. The filtrate was washed with water (2 x30 ml) and dried. The solvent was removed and the residue was chromatographed using EtOAc -hexane to give (9*S)-2/-O,3/-iV-bis(benzyloxycarbonyl)-iV-demethyl-9-O, l l -O-«-propylidene-9-dihydroerythromycin A as a colourless gum (105 mg). The above product was converted into the title compound using the process described for the preparation of compound 8a. The title compound was obtained as colourless crystals (70 mg Compounds8d and 8e were prepared similarly.
A (200 mg) in dry, ethanol -free CHC13 (2 ml) treated with piperonaldehyde dimethyl acetal (500 mg) and pyridinium /?-toluenesulfonate (80 mg). The solution was kept for 7 days, and was then diluted with ethyl acetate and washed with K2CO3soln and water. The solution was dried, the solvent was removed, and the residue was chromatographed using 35%am-monia-MeOH-CHC13(1 :9 :90) to give a white foam. The foam was then chromatographed on silanised silica gel using MeOH-phosphate buffer (0.067 m, pH 7.0) (3 : 2) to give the title compound as colourless prisms (180 mg Compounds 8h, 8i, 8j and 8k were prepared similarly.
(95)-9-Q , l l -O-Methoxymethylene-9-dihydroerythromycin A (8m) (9£)-9-Dihydroerythromycin A (200 mg) in dry, ethanol -free CHC13 (2 ml) was treated with trimethyl orthoformate (1 ml) and pyridinium /?-toluenesulfonate (70 mg) and the mixture was stirred for 6 days. The mixture was diluted with ethyl acetate and washed with 10% K2CO3soln and water. The solution was dried and the solvent was removed to yield a colourless gum(230 mg). The gum was dissolved in MeOH(8 ml) and acetic acid (0.1 ml) was added1; The solution was kept for 24 hours and was then diluted with ethyl acetate and washed with NaHCO3soln and water. The solution was dried, the solvent was removed, and the residue was chromatographed on silanised silica gel using MeOH-phosphate buffer (0.067 m, pH 7.0) (3 :2) to give the title compound (96')-9-O, l l -O-Isopropylidene-9-dihydroerythromycin A (9) (9S)-9-Dihydroerythromycin A (500 mg) and 2-methoxypropene (0.7 ml) were dissolved in dry, EtOH -free CHC13(10 ml). Pyridinium chloride (120 mg) was added and the mixture was stirred for 16 hours. The solution was washed with 10% K2CO3soln and then dried. The solvent was removed and the residue was dissolved in a mixture of acetone (10 ml) and water (10 ml). The solution was brought to pH 3.5 using 1 m HC1, and was kept for 2 hoursn. The solution was basified (pH ll) using K2CO3 and was extracted with ethyl acetate. The extract was dried, the solvent was removed, and the residue was chromatographed on silanised silica gel using MeOH-phosphate buffer (95)-9-Dihydroerythromycin A Cyclic 9,1 1-Carbonate (10) (9S)-9-Dihydroerythromycin A (370 mg) in dry THF (3 ml) was treated with K2CO3 powder (300 mg) and carbonyl diimidazole (100 mg) and the mixture was stirred for 22 hours, then diluted with ethyl acetate and washed twice with water. The solution was dried, the solvent was removed, and the (95)-9-O-(2-Methoxyethoxymethyl)-9-dihydroerythromycin A (1 1) (95)-2/-O,3/-iV-Bis(benzyloxycarbonyl)-A^demethyl-9-dihydroerythromycin A (6) (200 mg) in dry 1,2-dimethoxyethane (2 ml) was treated with sodium hydride (50% dispersion in oil; 10 mg) and the mixture was stirred for 5 minutes. 2-Methoxyethoxymethyl chloride (40 mg) was added and the mixture was stirred for 40 minutes. The mixture was diluted with ethyl acetate and washed with water, NaHCO3 soln, and water. The solution was dried, the solvent was removed, and the residue was chromatographed using EtOAc -hexane to give (95) The above compoundwas converted into the title compoundusing the process described for the preparation of compound8a. The title compoundll was obtained as a colourless gum (90 mg):
[a]g -31.9°(c 1.0); EI-MS m/z 823 (M, found 823.5285; calcd for C41H77NO15 823.5297).
